H.R. 5316, known as the Drug Shortage Compounding Patient Access Act of 2025, aims to address the issue of drug shortages in the U.S. by improving access to compounded medications for patients. The bill likely includes measures to streamline the compounding process and enhance the ability of pharmacies to produce necessary medications when commercial products are unavailable.
The Drug Shortage Compounding Patient Access Act of 2025 is a proactive step towards ensuring that patients have timely access to essential medications during shortages. By facilitating the compounding of drugs, the legislation supports healthcare providers in meeting patient needs and addresses a critical gap in the pharmaceutical supply chain.
While the Drug Shortage Compounding Patient Access Act of 2025 aims to tackle drug shortages, critics express concerns about the potential risks associated with increased compounding practices. There are fears that the bill could lead to quality control issues and compromise patient safety if not adequately regulated.
The Drug Shortage Compounding Patient Access Act of 2025, sponsored by Diana Harshbarger, has significant financial backing from the health professionals sector, totaling $120 million. This substantial amount raises concerns about potential conflicts of interest, as the bill directly pertains to health-related issues, specifically drug shortages. The overlap between the sponsor's top donor industry and the bill's subject matter suggests that the interests of these donors could influence legislative outcomes in favor of the health sector, potentially at the expense of broader public health considerations.
Additionally, while the sponsor has received donations from the retired sector amounting to $37.5 million, it is the health professionals' contributions that pose a more immediate concern due to their direct relevance to the bill. The lobbying activities surrounding this bill, although undisclosed, further complicate the situation, as they may involve entities with vested interests in the outcome of the legislation. Voters should be aware of these financial connections and consider how they might impact the integrity of the legislative process.
These industries are both affected by this bill and among the sponsor's top donors.
| Industry | Match Type | Related Subject | Donations |
|---|---|---|---|
| Health Professionals (H01) | Sector | Health | $120,000,000 |
| Total from overlapping industries | $120,000,000 | ||
Organizations that lobbied on issues related to this bill's policy area.
| Client | Lobbying Firm | Amount |
|---|---|---|
| WELLS FARGO & COMPANY | RMP STRATEGIES, LLC | $10,000 |
| MANAGED FUNDS ASSOCIATION | RMP STRATEGIES, LLC | $10,000 |
| DISABILITY RIGHTS EDUCATION & DEFENSE INC | DISABILITY RIGHTS EDUCATION & DEFENSE, INC. | $10,000 |
| SAMSARA INC. | CORNERSTONE GOVERNMENT AFFAIRS, INC. | undisclosed |
| OTG | PAUL HASTINGS LLP | undisclosed |
| BLOCKQUAKE HOLDINGS LLC | PAUL HASTINGS LLP | undisclosed |
| PAYSAFE MERCHANT SERVICES CORPORATION | PAUL HASTINGS LLP | undisclosed |
| PROOF OF STAKE ALLIANCE | PAUL HASTINGS LLP | undisclosed |
| INTEGRAL COMMUNITIES | PAUL HASTINGS LLP | undisclosed |
| SENTILINK CORP. | PAUL HASTINGS LLP | undisclosed |
| TEMPLUM LLC (FORMERLY KNOWN AS OUISA CAPITAL LLC) | PAUL HASTINGS LLP | undisclosed |
| GLOBAL PRIMEX LLC | PAUL HASTINGS LLP | undisclosed |
| WARRIOR TRADING | PAUL HASTINGS LLP | undisclosed |
| SYNIVERSE TECHNOLOGIES LLC | PAUL HASTINGS LLP | undisclosed |
| SOUTHERN INSTITUTE OF POLICY RESEARCH | SOUTHERN INSTITUTE OF POLICY RESEARCH | undisclosed |
Source: Senate Lobbying Disclosure Act (LDA) filings, 2026
Top industries funding Diana Harshbarger, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
